AAPL   397.67 (+3.65%)
MSFT   215.14 (+0.69%)
FB   249.33 (+1.74%)
GOOGL   1,571.99 (+2.14%)
AMZN   3,317.37 (+3.67%)
NVDA   426.50 (+1.75%)
BABA   259.95 (-0.41%)
MU   50.77 (+0.14%)
GE   6.68 (-0.15%)
ACB   12.21 (+1.58%)
GILD   77.35 (+1.35%)
DIS   119.30 (-0.03%)
BAC   24.00 (-0.08%)
AAPL   397.67 (+3.65%)
MSFT   215.14 (+0.69%)
FB   249.33 (+1.74%)
GOOGL   1,571.99 (+2.14%)
AMZN   3,317.37 (+3.67%)
NVDA   426.50 (+1.75%)
BABA   259.95 (-0.41%)
MU   50.77 (+0.14%)
GE   6.68 (-0.15%)
ACB   12.21 (+1.58%)
GILD   77.35 (+1.35%)
DIS   119.30 (-0.03%)
BAC   24.00 (-0.08%)
AAPL   397.67 (+3.65%)
MSFT   215.14 (+0.69%)
FB   249.33 (+1.74%)
GOOGL   1,571.99 (+2.14%)
AMZN   3,317.37 (+3.67%)
NVDA   426.50 (+1.75%)
BABA   259.95 (-0.41%)
MU   50.77 (+0.14%)
GE   6.68 (-0.15%)
ACB   12.21 (+1.58%)
GILD   77.35 (+1.35%)
DIS   119.30 (-0.03%)
BAC   24.00 (-0.08%)
AAPL   397.67 (+3.65%)
MSFT   215.14 (+0.69%)
FB   249.33 (+1.74%)
GOOGL   1,571.99 (+2.14%)
AMZN   3,317.37 (+3.67%)
NVDA   426.50 (+1.75%)
BABA   259.95 (-0.41%)
MU   50.77 (+0.14%)
GE   6.68 (-0.15%)
ACB   12.21 (+1.58%)
GILD   77.35 (+1.35%)
DIS   119.30 (-0.03%)
BAC   24.00 (-0.08%)
Log in

NASDAQ:CYCNCyclerion Therapeutics Stock Price, Forecast & News

$5.11
-0.27 (-5.02 %)
(As of 07/13/2020 12:02 PM ET)
Add
Compare
Today's Range
$4.87
Now: $5.11
$5.27
50-Day Range
$3.86
MA: $5.19
$7.14
52-Week Range
$1.69
Now: $5.11
$14.83
Volume11,410 shs
Average Volume277,173 shs
Market Capitalization$141.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.37
There is no company description available for Cyclerion Therapeutics Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCN
CUSIPN/A
CIKN/A
Phone857-327-8778

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.51 million
Book Value$3.56 per share

Profitability

Net Income$-123,010,000.00
Net Margins-1,917.30%

Miscellaneous

EmployeesN/A
Market Cap$141.80 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive CYCN News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.

Cyclerion Therapeutics (NASDAQ:CYCN) Frequently Asked Questions

How has Cyclerion Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Cyclerion Therapeutics' stock was trading at $2.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYCN shares have increased by 76.2% and is now trading at $5.11. View which stocks have been most impacted by Coronavirus.

When is Cyclerion Therapeutics' next earnings date?

Cyclerion Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Cyclerion Therapeutics.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics Inc (NASDAQ:CYCN) released its earnings results on Monday, May, 4th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.14. The business had revenue of $1.01 million for the quarter. Cyclerion Therapeutics had a negative return on equity of 96.31% and a negative net margin of 1,917.30%. View Cyclerion Therapeutics' earnings history.

Has Cyclerion Therapeutics been receiving favorable news coverage?

News headlines about CYCN stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyclerion Therapeutics earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Cyclerion Therapeutics.

Are investors shorting Cyclerion Therapeutics?

Cyclerion Therapeutics saw a decrease in short interest in June. As of June 30th, there was short interest totaling 823,400 shares, a decrease of 16.8% from the June 15th total of 990,200 shares. Based on an average daily trading volume, of 229,800 shares, the short-interest ratio is currently 3.6 days. Currently, 3.6% of the company's shares are sold short. View Cyclerion Therapeutics' Current Options Chain.

Who are some of Cyclerion Therapeutics' key competitors?

What other stocks do shareholders of Cyclerion Therapeutics own?

What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $5.11.

How big of a company is Cyclerion Therapeutics?

Cyclerion Therapeutics has a market capitalization of $141.80 million and generates $4.51 million in revenue each year.

What is Cyclerion Therapeutics' official website?

The official website for Cyclerion Therapeutics is www.cyclerion.com.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.